Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Insulinoma
- [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
- The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
- Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia
- Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
- Pasireotide in Hyperinsulinemic Hypoglycemia
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
- 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
- 18F-FDOPA PET in Neuroendocrine Tumours
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
- Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
- 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors